PubMed HealthSearch

Biomedical subjects

J Moragas

Publications and source records attributed to J Moragas.

2 recordsLinked to original sources

Clinically prescribed sunscreen (sun protection factor 15) does not decrease serum vitamin D concentration sufficiently either to induce changes in parathyroid function or in metabolic markers.

Some studies have suggested that the use of sunscreens to prevent skin cancer may put the population at risk of vitamin D deficiency. We followed 24 sunscreen users and 19 controls over 2 years, including two summers, two winters and a basal period (winter). Vitamin D, parathormone and bone biological markers were evaluated each season. Mean levels of 25-hydroxyvitamin D rose in summer, with the increments being significantly higher for the second year in the control group. Levels decreased in winter in both groups, and were significantly lower in sunscreen users. We did not observe any significant change in parathormone, tartrate resistant phosphatase, total alkaline phosphatase, osteocalcin, urine hydroxyproline or urine calcium. Clinically prescribed sunscreen creams (sun protection factor 15) caused a minor decrease in 25-hydroxyvitamin D levels, which did not induce secondary hyperparathyroidism or an increment in bone biological markers.

Aged

An overview of two comparative multicentre trials with halometasone/triclosan cream in acute superficial bacterial skin infections.

Two multicentre, open comparative trials were carried out by seven dermatologists in Spain and Yugoslavia in 220 evaluable patients with acute superficial skin infections. In these trials halometasone/triclosan cream showed an overall success rate ('good' and 'very good' results) of 84% as against 60% obtained with the comparative preparations. With regard to therapeutic effect halometasone/triclosan cream proved significantly superior to fluocinolone acetonide/neomycin cream (p less than 0.001) and yielded a higher overall success rate, although not statistically significant, than that observed with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream (75% versus 57%). The halometasone/triclosan cream was well tolerated: the incidence of unwanted effects was significantly lower (p less than 0.05) than that with fluocinolone acetonide/neomycin cream and equal to that with fluprednylidene acetate/gentamicin/chlorohydroxyquinoline cream.

Administration, Topical